4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• 4D Molecular Therapeutics' stock has been assigned a "Sell (D-)" rating by Weiss Ratings, indicating concerns about the company's financial health.
• Despite Weiss Ratings' negative outlook, 8 other analysts have rated the stock as a "Buy," with an average target price of $30.40.
• In its latest quarterly earnings, 4D Molecular Therapeutics reported a loss of ($0.98) earnings per share, which was below analysts' expectations, highlighting ongoing financial challenges.

Weiss Ratings reiterated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a research report released on Saturday, September 13th,Weiss Ratings reports.

Several other equities analysts have also recently issued reports on FDMT. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Roth Capital reduced their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Trading Down 7.0%

FDMT stock traded down $0.50 during midday trading on Friday, hitting $6.60. The company had a trading volume of 1,185,517 shares, compared to its average volume of 516,653. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $13.59. The stock's 50 day moving average price is $5.95 and its 200 day moving average price is $4.44. The stock has a market cap of $308.22 million, a price-to-earnings ratio of -1.87 and a beta of 2.86.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. Analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after purchasing an additional 1,337,497 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth about $532,000. Harbor Capital Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth about $99,000. Two Sigma Investments LP raised its position in shares of 4D Molecular Therapeutics by 196.3% in the 4th quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock worth $1,749,000 after purchasing an additional 208,021 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock worth $91,000 after purchasing an additional 3,783 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.